Ecog-acrin Cancer Research Group
Clinical trials sponsored by Ecog-acrin Cancer Research Group, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New MRI technique could sharpen prostate cancer staging Results expected Dec 2026 (estimated)
- New drug combos tested to improve lymphoma control in younger patients Results expected Dec 2026 (estimated)
- Massive myeloma trial tests which combo works best Results expected Dec 2026 (estimated)
- Green tea extract tested to keep prostate cancer in check Results expected Dec 2026 (estimated)
- PET scans may let melanoma patients stop treatment sooner Results expected Jan 2027 (estimated)
-
Can a gene test guide better treatment for head and neck cancer survivors?
Disease control Recruiting nowThis study compares two treatments after surgery for stage III-IVA head and neck cancer: radiation alone versus radiation plus the chemotherapy drug cisplatin. The goal is to see which approach better prevents the cancer from returning, especially in patients with certain TP53 ge…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
PET scans guide new combo therapy to fight returning prostate cancer
Disease control Recruiting nowThis Phase III trial is testing whether using PET scans to guide treatment can help men whose prostate cancer has returned after surgery. For those without signs of spread outside the pelvis, researchers are adding a drug called apalutamide (plus other hormones) to standard radia…
Phase 3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Chemotherapy directly into the belly: a new hope for advanced stomach cancer?
Disease control Recruiting nowThis study tests whether giving the chemotherapy drug paclitaxel directly into the abdominal cavity, along with standard intravenous chemo, can help people with stomach cancer that has spread to the lining of the abdomen. About 148 adults with this condition will be randomly assi…
Phase 2/3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Could four drugs be better than three for myeloma?
Disease control Recruiting nowThis phase 3 trial compares a four-drug combination (daratumumab, bortezomib, lenalidomide, and dexamethasone) against a three-drug regimen (daratumumab, lenalidomide, and dexamethasone) in 1,450 people with newly diagnosed multiple myeloma who are not candidates for early stem c…
Phase 3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New drug cocktail aims to halt smoldering myeloma before it strikes
Disease control Recruiting nowThis study tests whether adding daratumumab to standard lenalidomide and dexamethasone can improve survival in people with high-risk smoldering myeloma, a condition that often progresses to active cancer. About 288 participants will receive either the standard two-drug regimen or…
Phase 3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Liver pump chemotherapy may boost survival in advanced colorectal cancer
Disease control Recruiting nowThis phase 3 trial is testing whether adding a chemotherapy pump that delivers drugs directly to the liver (hepatic arterial infusion, or HAI) can help people with colorectal cancer that has spread to the liver and cannot be removed by surgery. About 408 participants will receive…
Phase 3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New study pits two drug combos against stubborn thyroid cancer
Disease control Recruiting nowThis phase III trial is for people with a specific type of thyroid cancer (BRAF V600E-mutated) that doesn't respond to radioactive iodine. It compares two treatment options: a combination of dabrafenib and trametinib versus cabozantinib alone. The goal is to see which is safer an…
Phase 3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Broccoli compound put to the test against melanoma
Prevention Recruiting nowResearchers are testing whether sulforaphane, a substance found in broccoli and other cruciferous vegetables, can prevent melanoma in people who have multiple atypical moles and a prior history of melanoma. Participants take sulforaphane or a placebo by mouth. The trial measures …
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Prevention
Last updated Sep 17, 2026 00:00 UTC
-
Can smarter monitoring of pancreatic cysts prevent cancer?
Knowledge-focused Recruiting nowThis study compares two ways of monitoring pancreatic cysts—more frequent versus less frequent scans—and looks for biomarkers in the blood that might help predict cancer risk. About 770 adults aged 50 to 75 with at least one cyst will take part. The goal is to find out which moni…
Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
New imaging trial aims to solve brain tumor scan confusion
Knowledge-focused Recruiting nowThis phase II trial is testing whether advanced imaging techniques like DSC-MRI and PET scans can better distinguish actual tumor growth from treatment-related changes in people with newly diagnosed glioblastoma. The study will enroll 100 adults who are receiving standard treatme…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC